1. Introduction: Why Platform Choice Matters in Exosomal RNA Profiling
Exosomal RNA profiling has emerged as a pivotal tool in understanding intercellular communication, disease biomarkers, and therapeutic targets. Exosomes, the nano-sized extracellular vesicles, carry a rich cargo of RNAs, including mRNAs, miRNAs, and lncRNAs, reflecting the physiological and pathological state of their cells of origin.
Selecting the appropriate platform for exosomal RNA analysis is crucial, as it influences the sensitivity, specificity, throughput, and overall success of the study. The three predominant platforms are:
- Next-Generation Sequencing (NGS): Offers high-throughput, comprehensive profiling, ideal for discovering novel RNAs.
- Quantitative PCR (qPCR): Provides high sensitivity and specificity for known targets, suitable for validation studies.
- Microarrays: Enable simultaneous analysis of multiple known RNAs, balancing throughput and cost.
For a foundational understanding of exosomal RNA sequencing, refer to The Beginner's Guide to Exosome RNA-Seq.
2. Overview of Available Platforms
A comparative overview of the three platforms is presented below:
| Platform |
Detection Principle |
Sensitivity |
Throughput |
Suitable For |
| NGS |
High-throughput sequencing |
High |
Very High |
Discovery, profiling of novel RNAs |
| qPCR |
Fluorescent quantification |
Very High |
Low |
Targeted validation of known RNAs |
| Microarrays |
Hybridization-based detection |
Medium |
Medium |
Profiling of known RNA panels |
3. Platform Deep Dive
NGS has revolutionized the field of transcriptomics by enabling high-throughput sequencing of RNA molecules, including those encapsulated within exosomes. Its unparalleled sensitivity and depth make it an ideal choice for comprehensive profiling of exosomal RNA species, including small RNAs, long non-coding RNAs (lncRNAs), and microRNAs (miRNAs).
Advantages:
- Discovery of Novel RNAs: NGS does not require prior knowledge of RNA sequences, allowing for the identification of novel exosomal RNA species that may serve as potential biomarkers or therapeutic targets.
- Quantitative Analysis: It provides quantitative data on RNA abundance, facilitating differential expression analyses across different conditions or disease states.
- Isoform Detection: NGS can distinguish between different RNA isoforms, offering insights into alternative splicing events within exosomal RNA populations.
Case Study:
A study by Vallejos et al. (2023) performed RNA sequencing on plasma exosomes from colon cancer patients and healthy controls. They identified a gene signature, ExoSig445, consisting of 445 differentially expressed genes that could distinguish colon cancer patients from healthy individuals with high accuracy. This suggests the potential of exosomal RNA sequencing as a non-invasive diagnostic tool for colon cancer.
Considerations:
- Cost and Complexity: NGS is relatively expensive and requires sophisticated bioinformatics tools and expertise for data analysis.
- Sample Quality: High-quality RNA is essential for reliable sequencing results, necessitating meticulous sample preparation and quality control measures.
b. Quantitative Polymerase Chain Reaction (qPCR)
qPCR is a widely used technique for the quantification of specific RNA targets. In the context of exosomal RNA analysis, it serves as a valuable tool for validating findings from high-throughput studies or for targeted analysis of known RNA species.
Advantages:
- High Sensitivity and Specificity: qPCR offers exceptional sensitivity, capable of detecting low-abundance RNAs with high specificity.
- Cost-Effectiveness: Compared to NGS, qPCR is more affordable and requires less complex instrumentation and data analysis.
- Rapid Turnaround: The technique allows for quick processing of samples, making it suitable for studies with time constraints.
Case Study:
Gorji-Bahri et al. (2021) conducted a study to identify stable reference genes for qPCR analysis of exosomal mRNA derived from liver and breast cancer cell lines. They evaluated eight candidate reference genes and found that GAPDH, YWHAZ, and UBC exhibited the most stable expression, providing reliable normalization for qPCR studies involving exosomal RNA.
Considerations:
- Requirement of Prior Knowledge: qPCR necessitates prior knowledge of target RNA sequences for primer design, limiting its use in exploratory studies.
- Limited Multiplexing: While multiplexing is possible, the number of targets that can be simultaneously analyzed is limited compared to high-throughput platforms.
Microarrays are hybridization-based platforms that allow for the simultaneous analysis of thousands of known RNA sequences. They have been employed in exosomal RNA studies to profile expression patterns across various conditions.
Advantages:
- High-Throughput Capability: Microarrays can assess the expression of a vast number of RNA targets in a single experiment.
- Cost-Effective for Large Studies: For studies focusing on known RNA sequences, microarrays offer a more economical option compared to NGS.
- Reproducibility: The standardized nature of microarray platforms ensures high reproducibility across experiments.
Case Study:
In a study by Wang et al. (2022), microarray analysis was used to profile circRNA expression in exosomes derived from bone marrow mesenchymal stem cells of postmenopausal osteoporosis patients. The researchers identified differentially expressed circRNAs, providing insights into the potential role of exosomal circRNAs in osteoporosis pathogenesis.
Considerations:
- Limited to Known Sequences: Microarrays can only detect RNA sequences that are represented on the array, making them unsuitable for novel RNA discovery.
- Lower Sensitivity: Compared to qPCR and NGS, microarrays have lower sensitivity, potentially missing low-abundance transcripts.
In summary, the choice of platform for exosomal RNA analysis should align with the specific objectives of the study:
- NGS is ideal for comprehensive profiling and discovery of novel RNA species.
- qPCR is best suited for targeted validation studies requiring high sensitivity and specificity.
- Microarrays offer a cost-effective solution for high-throughput analysis of known RNA sequences.
4. How to Match Platform to Your Research Goal
Biomarker Discovery: Next-Generation Sequencing (NGS)
NGS is the preferred platform for biomarker discovery due to its high-throughput capabilities and ability to detect novel RNAs without prior sequence knowledge. It allows comprehensive profiling of exosomal RNA, including small RNAs, lncRNAs, and miRNAs.
In a study by Zhang et al. (2020), NGS was utilized to profile exosomal RNAs in plasma samples from patients with acute myocardial infarction (AMI). The researchers identified specific exosomal long RNAs (exoLRs) that were differentially expressed in AMI patients compared to controls, suggesting their potential as biomarkers for AMI diagnosis.
A brief view of the workflow of human plasma exosomal long RNA-seq and its characteristics in each group.
Clinical Validation: Quantitative PCR (qPCR)
qPCR is ideal for validating known biomarkers in larger cohorts due to its high sensitivity, specificity, and cost-effectiveness. It requires prior knowledge of target sequences and is often used post-NGS to confirm findings.
A study titled "Circulating plasma exosomal miRNA profiles serve as potential biomarkers for hepatocellular carcinoma," published in Oncology Letters in 2021, exemplifies the application of qPCR in clinical validation. In this research, the investigators initially identified differentially expressed miRNAs through microarray analysis in plasma exosomes from HCC patients. Subsequently, they employed reverse transcription-quantitative PCR (RT-qPCR) to validate the expression levels of eight selected miRNAs in a larger cohort comprising 20 paired samples from HCC patients with and without lung metastasis. The validation confirmed that six exosomal miRNAs (let-7e, miR-27a, miR-221, miR-185, miR-20b, and miR-4454) were significantly upregulated, while two (miR-4720 and miR-5189) were downregulated in metastatic HCC cases compared to non-metastatic ones. This study underscores the efficacy of qPCR in validating potential biomarkers identified through high-throughput methods, facilitating their translation into clinical diagnostics.
Validation of differential exosomal miRNAs in plasma exosomes by reverse transcription-quantitative PCR
Comparative Expression Studies: Microarrays
Microarrays are suitable for comparing expression profiles across different conditions when focusing on known RNAs. They offer high-throughput analysis with good reproducibility and are more cost-effective than NGS. However, they are limited to pre-designed probe sets and are not ideal for detecting low-abundance or novel RNAs.
To assist you in selecting the most suitable platform for your exosomal RNA research, CD Genomics offers comprehensive services across Next-Generation Sequencing (NGS), quantitative PCR (qPCR), and microarray technologies. Our team of RNA experts provides end-to-end support, from experimental design to data analysis, ensuring tailored solutions for your specific research needs.
5. Case Example: Platform Choice in a Real Study
Study Overview
In the study titled "A Diagnostic Model Using Exosomal Genes for Colorectal Cancer," researchers aimed to develop a non-invasive diagnostic model for CRC by analyzing exosomal RNA profiles. They utilized RNA sequencing data from public databases, including exoRBase 2.0 and Gene Expression Omnibus (GEO), to identify differentially expressed exosomal genes between CRC patients and healthy controls.
Platform Selection and Rationale
Discovery Phase: NGS
The researchers began with NGS to perform a comprehensive analysis of exosomal RNA profiles. This high-throughput approach allowed for the identification of 38 common differentially expressed exosomal genes across multiple datasets. Advanced statistical methods, such as Least Absolute Shrinkage and Selection Operator (LASSO) and Support Vector Machine Recursive Feature Elimination (SVM-RFE), were employed to narrow down the list to six key exosomal genes: H3F3A, MYL6, FBXO7, TUBA1C, MEF2C, and BANK1.
Validation Phase: qPCR
Following the discovery phase, the study utilized qPCR to validate the expression levels of the six identified exosomal genes. Exosomes were isolated from CRC cell lines and human plasma samples, and the expression of the candidate genes was measured. The qPCR results confirmed that H3F3A, MYL6, and TUBA1C were significantly upregulated, while MEF2C and FBXO7 were downregulated in CRC samples compared to controls. BANK1 did not show significant differences.
Implications and Insights
This study exemplifies the strategic use of NGS for the broad discovery of potential biomarkers, followed by qPCR for targeted validation. The combination of these platforms enabled the researchers to develop a robust diagnostic model with high accuracy, demonstrating the importance of selecting appropriate technologies based on research objectives.
By integrating NGS and qPCR, the study effectively identified and validated exosomal RNA biomarkers for CRC, highlighting a practical approach to platform selection in exosomal RNA research.
Overall workflow of the present study.
6. Our Recommendation: Choosing the Right Service with Confidence
NGS Services: For In-Depth Discovery Projects
NGS is ideal for comprehensive profiling of exosomal RNA, enabling the discovery of novel RNAs, including small RNAs, lncRNAs, and miRNAs. Our exosomal RNA sequencing services include isolation from various sample types (e.g., serum, plasma, urine), library preparation, and high-throughput sequencing using platforms like Illumina and MGI. We provide detailed bioinformatics analyses, including differential expression, alternative splicing, and pathway enrichment analyses.
qPCR Services: For Targeted Validation Studies
qPCR is the gold standard for validating known biomarkers due to its high sensitivity, specificity, and cost-effectiveness. Our qPCR services support the validation of candidate exosomal RNAs identified through NGS or microarray analyses. We offer assay design, optimization, and data analysis to confirm the expression levels of specific targets across larger cohorts.
Microarray Services: For High-Throughput Expression Profiling
Microarrays are suitable for comparing expression profiles across conditions when focusing on known RNAs. Our microarray services provide high-throughput analysis with good reproducibility and are more cost-effective than NGS. We offer comprehensive support, including sample preparation, hybridization, scanning, and data interpretation.
Explore our services: Exosome RNA Sequencing
Expert Support from Experimental Design to Data Analysis
Our team of experienced scientists collaborates with you throughout the project lifecycle:
Experimental Design: We assist in selecting the appropriate platform and designing experiments tailored to your research objectives.
- Sample Preparation: Guidance on optimal sample collection, storage, and processing to ensure data quality.
- Data Analysis: Comprehensive bioinformatics support, including quality control, normalization, differential expression analysis, and functional annotation.
- Interpretation and Reporting: Detailed reports with actionable insights to facilitate publication and further research.
FAQ Section
-
-
Can I use NGS for small sample sizes?
-
Yes, with optimized protocols, NGS can be performed on limited input material. Our library preparation methods are designed to work with low RNA quantities, although amplification steps may be necessary to ensure sufficient material for sequencing.
-
-
How many targets can I run with qPCR?
Exosomal RNA Biomarkers
Sample Preparation Guide for Exosome RNA Sequencing
By leveraging CD Genomics' comprehensive services and expert support, you can confidently select the appropriate platform for your exosomal RNA research, ensuring high-quality data and meaningful insights.
References:
- Gorji-Bahri G, Moradtabrizi N, Vakhshiteh F, Hashemi A. Validation of common reference genes stability in exosomal mRNA-isolated from liver and breast cancer cell lines. Cell Biol Int. 2021 May;45(5):1098-1110. doi: 10.1002/cbin.11556. Epub 2021 Feb 4. PMID: 33501690. DOI: 10.1002/cbin.11556
- Fu M, Fang L, Xiang X, Fan X, Wu J, Wang J. Microarray analysis of circRNAs sequencing profile in exosomes derived from bone marrow mesenchymal stem cells in postmenopausal osteoporosis patients. J Clin Lab Anal. 2022 Jan;36(1):e23916. doi: 10.1002/jcla.23916. Epub 2021 Nov 19. PMID: 34799880; PMCID: PMC8761433. doi: 10.1002/jcla.23916
- Vallejos PA, Gonda A, Yu J, Sullivan BG, Ostowari A, Kwong ML, Choi A, Selleck MJ, Kabagwira J, Fuller RN, Gironda DJ, Levine EA, Hughes CCW, Wall NR, Miller LD, Senthil M. Plasma Exosome Gene Signature Differentiates Colon Cancer from Healthy Controls. Ann Surg Oncol. 2023 Jun;30(6):3833-3844. doi: 10.1245/s10434-023-13219-7. Epub 2023 Mar 2. PMID: 36864326; PMCID: PMC10175396. doi: 10.1245/s10434-023-13219-7
- Sun, Y., Wang, W., Tang, Y. et al. Microarray profiling and functional analysis of differentially expressed plasma exosomal circular RNAs in Graves' disease. Biol Res 53, 32 (2020). https://doi.org/10.1186/s40659-020-00299-y
- Vallejos, P.A., Gonda, A., Yu, J. et al. Plasma Exosome Gene Signature Differentiates Colon Cancer from Healthy Controls. Ann Surg Oncol 30, 3833–3844 (2023). https://doi.org/10.1245/s10434-023-13219-7
- He GD, Huang YQ, Liu L, Huang JY, Lo K, Yu YL, Chen CL, Zhang B, Feng YQ. Association of Circulating, Inflammatory-Response Exosomal mRNAs With Acute Myocardial Infarction. Front Cardiovasc Med. 2021 Aug 19;8:712061. doi: 10.3389/fcvm.2021.712061. PMID: 34490374; PMCID: PMC8418229. doi: 10.3389/fcvm.2021.712061
- Huang C, Tang S, Shen D, Li X, Liang L, Ding Y, Xu B. Circulating plasma exosomal miRNA profiles serve as potential metastasis-related biomarkers for hepatocellular carcinoma. Oncol Lett. 2021 Feb;21(2):168. doi: 10.3892/ol.2021.12429. Epub 2021 Jan 4. PMID: 33552286; PMCID: PMC7798106. doi: 10.3892/ol.2021.12429
- Lei T, Zhang Y, Wang X, Liu W, Feng W, Song W. A Diagnostic Model Using Exosomal Genes for Colorectal Cancer. Front Genet. 2022 Jul 15;13:863747. doi: 10.3389/fgene.2022.863747. PMID: 35910195; PMCID: PMC9334773. doi: 10.3389/fgene.2022.863747
